Cited by 379Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Opioid Use

The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain

Fox, Alyson, Kesingland, Adam, Gentry, Clive, McNair, Kara, Patel, Sadhana, Urban, Laszlo, James, Iain·2001·Pain

Abstract

We have examined the effects of cannabinoid agonists on hyperalgesia in a model of neuropathic pain in the rat and investigated the possible sites of action. The antihyperalgesic activity of the cannabinoids was compared with their ability to elicit behavioural effects characteristic of central cannabinoid activity. WIN55,212-2 (0.3-10 mg kg(-1)), CP-55,940 (0.03-1 mg kg(-1)) and HU-210 (0.001-0.03 mg kg(-1)) were all active in a 'tetrad' of tests consisting of tail-flick, catalepsy, rotarod and hypothermia following subcutaneous administration, with a rank order of potency in each of HU-210 > CP-55,940 > WIN55,212-2. The effects of WIN55,212-2 in each assay were blocked by the Cannabinoid1 (CB1) antagonist SR141716A. In the partial sciatic ligation model of neuropathic pain WIN55,212-2, CP-55,940 and HU-210 produced complete reversal of mechanical hyperalgesia within 3 h of subcutaneous administration with D50 values of 0.52, 0.08 and 0.005 mg kg(-1), respectively. In this model WIN55,212-2 was also effective against thermal hyperalgesia and mechanical allodynia. WIN55,212-2 produced pronounced reversal of mechanical hyperalgesia following intrathecal administration that was blocked by the CB1 antagonist SR141716A. Following intraplantar administration into the ipsilateral hindpaw, WIN55,212-2 produced up to 70% reversal of mechanical hyperalgesia, although activity was also observed at high doses following injection into the contralateral paw. The antihyperalgesic effect of WIN55,212-2 injected into the ipsilateral paw was blocked by subcutaneously administered SR141716A, but was not affected by intrathecally administered SR141716A. These data show that cannabinoids are highly potent and efficacious antihyperalgesic agents in a model of neuropathic pain. This activity is likely to be mediated via an action in both the CNS and in the periphery.

Integrity signals

Registry

Crossref · 10.1016/s0304-3959(00)00474-7

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies report efficacy of mixed cannabinoid CB1/CB2 agonists in the Seltzer model, although CNS side-effects were observed in the same dose range that resulted in full reversal of neuropathic nociception.

    “Several studies report efficacy of mixed cannabinoid CB1/CB2 agonists in this model, although CNS side-effects were nonetheless observed in the same dose range that resulted in full reversal of neuropathic nociception.68”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I.
Affiliations
Novartis (Switzerland) (CH)
Corresponding author
Fox, Alyson
Venue
Pain
Published
2001-05
Volume
92
Issue
1
Pages
91-100
ISSN
0304-3959 (ISSN-L)
OpenAlex
W1968426375
Cited by
379
References
35
Citations by year
2026: 3 · 2025: 2 · 2024: 8 · 2023: 7 · 2022: 5 · 2021: 11 · 2020: 9 · 2019: 13 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 8 · 2014: 8 · 2013: 15 · 2012: 22
FWCI
13.36
Type
journal article
Language
en
Open access
closed
Locations
  • Pain (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
cannabinoid 1 receptor, CB1 receptor, neuropathic pain, antihyperalgesia, WIN 55,212-2, CP55,940, HU-210, SR141716A, mechanical hyperalgesia, thermal hyperalgesia, mechanical allodynia, intrathecal administration, intraplantar administration
MeSH terms
Rimonabant, Analgesics, Animals, Cannabinoids, Cyclohexanols, Disease Models, Animal, Hyperalgesia, Morpholines, Naphthalenes, Pain Measurement, Piperidines, Pyrazoles, Receptors, Drug, Sciatica, Dronabinol, Rats, Wistar, Receptors, Cannabinoid, Benzoxazines, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review